全球肝病诊断市场

预计到 2030 年全球肝病诊断市场规模将达到 496 亿美元

全球肝病诊断市场规模预计在2024年为366亿美元，预计在分析期间（2024-2030年）将以5.2%的复合年增长率成长，到2030年将达到496亿美元。临床检测是本报告分析的细分市场之一，预计其复合年增长率为5.4%，到分析期结束时将达到168亿美元。诊断影像细分市场在分析期间内的复合年增长率预计为3.9%。

美国市场规模估计为 100 亿美元，中国市场预计复合年增长率为 8.3%

美国肝病诊断市场规模预计在2024年达到100亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到99亿美元，在2024-2030年的分析期间内，复合年增长率为8.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为2.5%和5.2%。在欧洲，预计德国市场的复合年增长率为3.4%。

全球肝病诊断市场－主要趋势与驱动因素摘要

为什么肝病诊断变得越来越重要

肝炎、脂肪肝、肝硬化和肝细胞癌 (HCC) 等肝病的发生率不断上升，推动了对先进诊断解决方案的需求。饮酒、肥胖和代谢紊乱等生活方式因素会加剧肝病，这仍然是全球沉重的健康负担。非酒精性脂肪肝病 (NAFLD) 和非酒精性脂肪性肝炎 (NASH) 的发生率不断上升，进一步凸显了早期准确诊断的必要性。传统的诊断方法，例如肝功能检查、影像技术和切片检查，正逐渐被基于生物标记的先进检测、非侵入性影像解决方案和人工智慧主导的诊断平台所补充。世界各国政府和医疗机构认识到及时干预对于降低发病率和死亡率的重要性，正在提高对早期疾病检测的认识并加大投入。此外，个人化医疗的趋势进一步推动了对创新肝病诊断工具的需求，这些工具能够根据个别风险因素和病情进展制定个人化的治疗方案。

哪些技术创新正在增强肝病诊断？

技术进步显着提高了肝病诊断的准确性、效率和可及性。最显着的创新之一是弹性成像等非侵入性诊断技术的开发，该技术无需切片检查即可评估肝臟硬度和检测纤维化。人工智慧成像解决方案也透过自动模式识别和预测分析增强了对肝臟异常的检测，从而彻底改变了诊断方法。液态切片技术的出现也具有突破性，它能够从血液样本中检测肝病生物标记物，减少了侵入性手术的需求。此外，整合基因组学、蛋白质组学和代谢体学的多体学正在为肝病的病理生理学和进展提供更深入的见解。远端医疗和远距离诊断解决方案的整合正在进一步扩大肝病筛检的可近性，尤其是在服务不足的地区。随着研发的不断深入，下一代诊断工具将在提高全球肝病患者的早期发现率和治疗效果方面发挥关键作用。

消费者趋势和医疗保健政策如何影响市场？

不断变化的消费者偏好和不断发展的医疗政策在肝病诊断市场的成长中发挥关键作用。人们对肝臟健康和预防性筛检的认识不断提高，促使越来越多的人寻求定期诊断检测，尤其是在高风险族群中。家用检测套组健康解决方案的普及，使消费者能够更方便地进行肝病诊断。此外，政府倡导早期检测的措施和公共卫生宣传活动也推动了对筛检计画的需求。医疗保健提供者和保险公司也认识到早期肝病检测的成本效益，从而扩大了先进诊断检测的覆盖范围。此外，製药公司和诊断开发商之间的合作正在加速新型肝病诊断技术的商业化。全球对减轻慢性肝病负担的重视，促使监管机构加速审批创新诊断解决核准，以确保其市场渗透力和广泛应用。

推动肝病诊断市场成长要素有哪些？

肝病诊断市场的成长受到多种因素的推动，包括肝病盛行率的上升、技术进步以及医疗政策的支持。乙肝和C肝、非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）发生率的上升，对早期精准诊断工具的需求强劲。影像技术、生物标记发现和人工智慧主导的诊断平台的创新正在提高肝病检测的准确性和可及性。就地检验和携带式诊断设备的作用日益增强，增强了早期诊断和病患监测。此外，远端医疗和基于人工智慧的决策支援等数位医疗技术的整合正在简化诊断工作流程并改善患者预后。对预防性医疗保健和定期肝功能筛检的日益重视，进一步推动了市场扩张。此外，对新型诊断技术的研发投入和监管支援的不断增加，确保了创新解决方案的稳定供应。随着全球医疗保健系统优先考虑早期疾病检测和个人化医疗，肝病诊断市场预计将持续成长，为改善患者照护和治疗策略铺平道路。

部分

诊断技术（实验室检查、影像学、内视镜检查、切片检查等）；疾病（NAFLD、NASH、纤维化、肝硬化、HCC等）；最终使用者（医院、实验室等）

受访公司范例

• Abbott
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Biosino Bio-Technology and Science Inc
• Boston Scientific Corporation
• DiaSorin
• Echosens
• Enterome
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fujifilm Corporation
• Genentech（a member of the Roche Group）
• Horiba Medical
• Laboratory Corporation of America Holdings（LabCorp）
• Owlstone Medical
• Perspectum
• Quest Diagnostics Incorporated
• Randox Laboratories Ltd.
• Siemens Healthineers
• Thermo Fisher Scientific Inc.

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地以及进出口情况（成品和原始OEM）预测其竞争地位的变化。这种复杂多变的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Liver Disease Diagnostics Market to Reach US$49.6 Billion by 2030

The global market for Liver Disease Diagnostics estimated at US$36.6 Billion in the year 2024, is expected to reach US$49.6 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$16.8 Billion by the end of the analysis period. Growth in the Imaging segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.0 Billion While China is Forecast to Grow at 8.3% CAGR

The Liver Disease Diagnostics market in the U.S. is estimated at US$10.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.9 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Liver Disease Diagnostics Market - Key Trends & Drivers Summarized

Why Is Liver Disease Diagnostics Gaining Critical Importance?

The increasing prevalence of liver diseases, including hepatitis, fatty liver disease, cirrhosis, and hepatocellular carcinoma (HCC), is driving the demand for advanced diagnostic solutions. Liver disease remains a significant global health burden, exacerbated by lifestyle factors such as alcohol consumption, obesity, and metabolic disorders. The rising incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has further intensified the need for early and accurate diagnostics. Traditional diagnostic methods such as liver function tests, imaging techniques, and biopsies are being supplemented by advanced biomarker-based assays, non-invasive imaging solutions, and AI-driven diagnostic platforms. Governments and healthcare organizations are increasing awareness and funding for early disease detection, recognizing the importance of timely intervention in reducing morbidity and mortality rates. Additionally, the shift towards personalized medicine is further fueling the need for innovative liver disease diagnostic tools, enabling tailored treatment approaches based on individual risk factors and disease progression.

What Innovations Are Enhancing Liver Disease Diagnostics?

Technological advancements are significantly improving the accuracy, efficiency, and accessibility of liver disease diagnostics. One of the most notable innovations is the development of non-invasive diagnostic techniques, such as elastography, which assesses liver stiffness and detects fibrosis without the need for a biopsy. AI-powered imaging solutions are also revolutionizing diagnostics by enhancing the detection of liver abnormalities through automated pattern recognition and predictive analytics. The emergence of liquid biopsy technology is another breakthrough, allowing for the detection of liver disease biomarkers in blood samples, reducing the need for invasive procedures. Additionally, multi-omics approaches, integrating genomics, proteomics, and metabolomics, are offering deeper insights into liver disease pathophysiology and progression. The integration of telemedicine and remote diagnostic solutions is further expanding access to liver disease screening, particularly in underserved regions. As research and development continue to advance, next-generation diagnostic tools will play a critical role in improving early detection rates and treatment outcomes for liver disease patients worldwide.

How Are Consumer Trends and Healthcare Policies Shaping the Market?

Shifting consumer preferences and evolving healthcare policies are playing a crucial role in the growth of the liver disease diagnostics market. The rising awareness of liver health and preventive screening is driving more individuals to seek regular diagnostic testing, particularly in high-risk populations. The adoption of at-home testing kits and digital health solutions is making liver disease diagnostics more convenient and accessible to consumers. Additionally, government initiatives and public health campaigns promoting early detection are fostering higher demand for screening programs. Healthcare providers and insurance companies are also recognizing the cost-effectiveness of early liver disease detection, leading to expanded coverage for advanced diagnostic tests. Furthermore, collaborations between pharmaceutical companies and diagnostic developers are accelerating the commercialization of novel liver disease diagnostic technologies. The global emphasis on reducing the burden of chronic liver conditions is driving regulatory agencies to fast-track approvals for innovative diagnostic solutions, ensuring wider market penetration and adoption.

What Are the Key Growth Drivers Fueling the Liver Disease Diagnostics Market?

The growth in the liver disease diagnostics market is driven by several factors, including the increasing prevalence of liver disorders, technological advancements, and supportive healthcare policies. The rising incidence of hepatitis B and C, NAFLD, and NASH is creating a strong demand for early and accurate diagnostic tools. Innovations in imaging techniques, biomarker discovery, and AI-driven diagnostic platforms are improving the precision and accessibility of liver disease detection. The expanding role of point-of-care testing and portable diagnostic devices is also enhancing early diagnosis and patient monitoring. Additionally, the integration of digital health technologies, such as telemedicine and AI-assisted decision support, is streamlining diagnostic workflows and improving patient outcomes. The growing focus on preventive healthcare and routine liver function screening is further bolstering market expansion. Moreover, increasing investments in research and development, coupled with regulatory support for novel diagnostic technologies, are ensuring a steady pipeline of innovative solutions. As global healthcare systems prioritize early disease detection and personalized medicine, the liver disease diagnostics market is expected to witness sustained growth, paving the way for improved patient care and treatment strategies.

SCOPE OF STUDY:

The report analyzes the Liver Disease Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Technique (Laboratory Tests, Imaging, Endoscopy, Biopsy, Others); Disease (NAFLD, NASH, Fibrosis, Cirrhosis, HCC, Others); End-Use (Hospitals, Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Biosino Bio-Technology and Science Inc
• Boston Scientific Corporation
• DiaSorin
• Echosens
• Enterome
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fujifilm Corporation
• Genentech (a member of the Roche Group)
• Horiba Medical
• Laboratory Corporation of America Holdings (LabCorp)
• Owlstone Medical
• Perspectum
• Quest Diagnostics Incorporated
• Randox Laboratories Ltd.
• Siemens Healthineers
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Liver Disease Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of NAFLD and NASH Throws the Spotlight on Advanced Liver Disease Diagnostics
  • OEM Innovation in Non-Invasive Biomarker Assays Drives Demand for Early Detection and Monitoring Tools
  • Expansion of Fibrosis and Cirrhosis Screening Programs Propels Use of Imaging and Blood-Based Diagnostic Platforms
  • Growth in Liver Transplant and Hepatology Clinics Spurs Adoption of High-Sensitivity Diagnostics
  • OEM Focus on AI-Driven Elastography and MRI Analysis Enhances Imaging Accuracy and Predictive Value
  • Regulatory Endorsements for Non-Invasive Diagnostics Accelerate Shift Away From Liver Biopsies
  • Surge in Point-of-Care Diagnostic Devices Enables Decentralized Liver Health Screening in Primary Care
  • OEM Development of Combined Liver Function Panels and Risk Scoring Tools Supports Integrated Clinical Decisions
  • Rising Prevalence of Metabolic Syndrome and Obesity Expands Addressable Population for Liver Diagnostics
  • OEM Partnerships With Pharma Companies Enable Companion Diagnostics in NASH and Hepatitis C Therapeutics
  • Growing Demand for Early-Stage Detection in Oncology Fuels Innovation in HCC-Specific Biomarker Panels
  • Expansion of Mobile Diagnostic Units and Community Health Initiatives Promotes Broader Access to Liver Testing
  • OEM Emphasis on Patient-Friendly Sample Collection Methods Enhances Compliance in Chronic Disease Monitoring
  • Regulatory Alignment on Diagnostic Performance Thresholds Supports Global Deployment of Standardized Tests
  • Increased Use of Liver Health Assessment in Pre-Operative Screening and Risk Stratification Drives Routine Testing
  • OEM Collaboration With Digital Health Providers Enables Remote Liver Health Monitoring and Data Integration
  • Growth in Awareness Campaigns and Preventive Health Check Programs Strengthens Uptake in Undiagnosed Populations
  • Rising Incidence of Alcohol-Related Liver Disease Supports Demand for Longitudinal Disease Monitoring Tools
  • OEM Strategies for Combining Genomic, Proteomic, and Metabolomic Data Enhance Diagnostic Precision
  • Focus on Diagnostic Value in Drug-Induced Liver Injury (DILI) Detection Expands Use in Pharmacovigilance Programs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Liver Disease Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Liver Disease Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Laboratory Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Laboratory Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Endoscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Diagnosis Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Diagnosis Techniques by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Diagnosis Techniques by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for NAFLD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for NAFLD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for NAFLD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for NASH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for NASH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for NASH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Cirrhosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Cirrhosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Cirrhosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Liver Disease Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 95: France Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 122: UK Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Liver Disease Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 179: India Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Liver Disease Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Liver Disease Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Liver Disease Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Liver Disease Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Liver Disease Diagnostics by Diagnosis Technique - Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Liver Disease Diagnostics by Diagnosis Technique - Percentage Breakdown of Value Sales for Laboratory Tests, Imaging, Endoscopy, Biopsy and Other Diagnosis Techniques for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Liver Disease Diagnostics by Disease - HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Liver Disease Diagnostics by Disease - Percentage Breakdown of Value Sales for HCC, Other Diseases, NAFLD, NASH, Fibrosis and Cirrhosis for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Liver Disease Diagnostics by End-Use - Hospitals, Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Liver Disease Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION